Progress of the AGC Group Medium-term Management Plan "AGC plus-2023"




AGC Inc.

February 8, 2022

AGC plus-2023 Financial Targets



- The *AGC plus-2023* financial targets have been achieved well ahead of schedule as structural reforms and business growth resulted in the profit increase in the core businesses and the growth of the strategic businesses.
- A drastic upward revision has been made to the FY2023 financial targets.



AGC plus-2023 Key Issues by Segment

efficiency



	-	
Ru	CIN	ess
Du		1633

Automotive

glass

Key issues

·Steadily pursuing productivity improvement and cost reduction to

improve profitability and capability for cash generation

• Expand value-added products including FLIV mask blanks

	Electronics	•Constantly generate new businesses	
Strategic Business	I ITE SCIENCE	•Expand business through timely investments •Achieve high growth based on the Group's global operations and technical-support capabilities	
	Mobility	 Steadily capture business opportunities amid market changes in the CASE era Start the mass production of car-mounted display glass in China to contribute to profit increase. 	
	Display	•Respond to the continuing demand increase in the Chinese market to build a long-term stable business foundation	
Core Business	Chlor-Alkali	•Further strengthen the business foundation in S.E. Asia through capacity enhancement in Thailand and Indonesia	
	Fluorochemical s & Specialty	 Capture the demand in global niche markets by adding value to products and domain expansion Change environmental challenges to business opportunities 	
	Architectural glass	Structural reforms toward the industrial realignment Minimize investments and integrate production to increase asset	

Direction

Further accelerate growth

Unchanged from the previous basic strategies

Accelerate structural reform

Structural Reform in Glass Businesses




- Initial target of the 15 billion yen reduction of fixed costs, etc. will be achieved as planned.
- Promote further structural reforms to improve profitability.

FY2020-21 FY2022-23 Structural reforms <Reduction of fixed costs> toward the industrial •Streamlining at the Europe HQ (including early realignment retirement) ·Closed a furnace in France Architectural Thorough cost Glass <Structural reform> reduction through •Transferred the architectural glass business in productivity North America improvement and •Transferred all the shares of Schott Gemtron fixed cost reduction Corporation Promote production <Reduction of fixed costs> consolidation by Streamlining at the Europe HQ and Czech introducing high-**Automotive** production sites efficiency facility and Glass Production consolidation by introducing highthereby reducing efficiency facilities (Reduced some production lines) production lines Cost reduction Approx. 12 billion yen/year (from FY2019) 3 billion yen +a

Chlor-Alkali Business: PVC market



- In FY2021, the supply-demand balance in the PVC market tightened dramatically as affected by the cold wave and hurricanes in North America and stricter environmental regulations in China.
- In FY2022 onward, the PVC market is expected to gradually soften. Yet, the supply-demand balance in Southeast Asia will remain tight.



China's Climate Change Policies

- 2021 Energy consumption reduction per unit of GDP by approx. 3%**
- 2025 Raise non-fossil fuel use to 20%***
- 2030 CO₂ emission peaking out
- 2030 Energy consumption reduction per unit of GDP by 65% or more
- 2030 Boost non-fossil fuel use to 25%
- 2060 Carbon neutrality


** : Compared with year 2005

***: Percentage of primary energy consumption

OP Target Achievement (To-be image)





■ While affected by the softening of the PVC Market, the operating profit will grow in both the strategic & core businesses.



AGC plus-2023 Performance by Segment (To-be image)








AGC plus-2023 CAPEX/Depreciation/R&D






ROCE by Segment (To-be image)




- Maintain the group-wide ROCE at 10% or higher
- Increase EBITDA* by approx. 60 billion yen (372.9 billion yen to 433 billion yen)



Sales Outlook for Strategic Business Products




- Every business will expand its scale of sales.
- Particularly biopharmaceutical CDMO will make a significant growth.



Outlook for Strategic Businesses




■ The strategic businesses are expected to grow steadily.



Capital Allocation Policy



- Increase the investments in the strategic businesses by 100 billion yen as compared to the previous plan.
- Accelerate asset sales, including all the available cross-held shares






Shareholder Return



- Steadily implement shareholder returns
- As stated in the Group's policy, flexibly implement share buyback while maintaining financial soundness and ensuring investment opportunities for growth businesses





Consolidated payout ratio

Share buyback (100 million JPY)

Consolidated total return ratio

Shareholder return policy

Total return ratio of 50% or higher

Maintain stable dividends with a consolidated dividend payout ratio of 40%, flexibly conduct share buyback



Appendix

FY2022-23 Premise



Risk factors	Impact on OP	Rate used	Supplementary info	
Dubai crude oil	260 million yen * loss if increased by 1 dollar per barrel	80USD	*excluding impact of oil hedging	
Chemicals market	 Caustic soda: \$1 M loss if the international market down by \$1 PVC spread: \$1.2M loss* if decreased by \$1 	_	*PVC spread: PVC market - (ethylene market×0.5)	
Exchange rate	700 million yen*loss if yen appreciated by 1%	1USD =115 yen	*Impact when all currencies fluctuate at the same proportion against JPY	

AGC plus-2023

Main investments and timeline for profit generation



	2020	2021	2022	2023	2024-		
Glass	China: New facility for car-mounted display cover glass						
Electro	China: Relocate furnace for 11th generation TFT LCD glass substrates						
	China: Capacity enhancement for 11th generation TFT LCD glass substrates						
nics	Japan: Drastic capacity enhancement for EUV photomask blanks						
	Japan: Double the capacity of EUV mask blanks						
	Indonesia: PVC capacity enhancement						
					acity enhancement of Chlor- Ili electrolytic facilities		
	Japan: Capacity enhancement for fluorine products						
	U.S.A.(Seattle): Capacity enhancement for biopharmaceuticals						
	U.S.A.(Boulder): Acquired biopharmaceuticals active ingredient plant of AstraZeneca						
Chemi	Denmark: Capacity enhancement for biopharmaceuticals						
cals	Italy: Acquired Molecular Medicine S.p.A, a developer of gene/cell therapy						
Cais	Italy: Capacity expansion of Genetic/Cell therapy CDMO						
	U.S.A. (Longmont): Acquired cell and gene therapy manufacturing facility						
	Germany: Newly built mRNA manufacturing facility						
	Spain: Capacity enhancement for synthesis pharmaceuticals						
					Japan: Production capacity enhancement of synthetic		

pharmaceuticals & agrochemicals





Disclaimer:

- ■This material is solely for information purposes and should not be construed as a solicitation. Although this material (including the financial projections) has been prepared using information we currently believe reliable, AGC Inc. does not take responsibility for any errors and omissions pertaining to the inherent risks and uncertainties of the material presented.
- ■We ask that you exercise your own judgment in assessing this material. AGC Inc. is not responsible for any losses that may arise from investment decisions based on the forecasts and other numerical targets contained herein.
- ■Copyright AGC Inc.

 No duplication or distribution without prior consent of AGC Inc.